Cambridge Healthtech Institute’s 3rd Annual

Lead Optimization for Drug Metabolism & Safety

Tools and Strategies for Predicting, Optimizing, and Improving PKPD and Safety

April 17, 2020



Lead compounds in drug discovery need to be optimized for both efficacy and safety. Unfortunately, some of the adverse events related to drug metabolism, clearance, and drug-drug interactions (DDI) do not surface until much later in drug development. This focused one-day symposium on Lead Optimization for Drug Metabolism & Safety will bring together experts from chemistry, ADME, DMPK, and pharmacology to talk about some of the factors that must be considered early in lead optimization for addressing safety concerns that may arise later. The symposium will cover some important concepts related to drug metabolism, biotransformation, drug transport, drug-drug interactions and more, using relevant case studies and recent research findings. It will offer an opportunity for attendees to network and share ideas with experts.


Preliminary Agenda

LEVERAGING IN SILICO TOOLS AND MACHINE LEARNING FOR ADME PREDICTIONS

FEATURED PRESENTATION: Artificial Intelligence and Small-Molecule Drug Metabolism

S. Joshua Swamidass, MD, PhD, Assistant Professor, Immunology and Pathology, Laboratory and Genomic Medicine; Faculty Lead, Translational Informatics, Institute for Informatics, Washington University

Integration of Structure-Based and Machine Learning Approaches to Predict Inhibition of Drug Metabolizing Enzymes

Maria A. Miteva, PhD, Research Director, Molécules Thérapeutiques in silico (MTi), Inserm Institute

EARLY PREDICTION OF DOSING AND COMPOUND SAFETY

Reactive Drug Metabolite Assessment in Drug Discovery and Development

Mark Grillo, PhD, Staff Scientist, Drug Metabolism & Pharmacokinetics, MyoKardia, Inc.

Understanding the Applicability and Limitations of in silico and in vitro Safety Models towards the Design and Selection of the Safest Drug Candidates

Takafumi Takai, PhD, Senior Scientist, Discovery Toxicology, Drug Safety Research & Evaluation, Takeda, Inc.

Model-Informed Human Pharmacokinetics and Dose Prediction: Beyond IVIVC of Compound Enzyme Stability

Yurong Lai, PhD, Senior Director, Drug Metabolism, Gilead Sciences

ADME STRATEGIES FOR NEW DRUG MODALITIES

Local Metabolism Leads to Better Understanding of Tissue Drug Concentration for New Modalities

Donglu Zhang, PhD, Principal Scientist, Drug Metabolism and Pharmacokinetics, Genentech, Inc.

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated
2019/10/31
Agenda,Sponsor updated